AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$CRL

Parisotto Shannon M sold $600K of CRL

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 2,039 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $294.12 ($0.60M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parisotto Shannon M
Published Aug 20, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The transaction is small relative to CRL's float and unlikely to affect market perception.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential upcoming regulatory or product developments not disclosed could influence insider behavior.

Relevance 4/10Novelty 4/10Timing: after‑market today

Background

Form 4 filings disclose insider trades; this filing reports a routine sale by a senior officer.

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

Officer Shannon M. Parisotto sold 2,039 shares for $599,710, reducing her stake to 4,807 shares via a 10b5‑1 plan.

Expected impact

No significant price impact expected.

Evidence & confidence

Sale size is modest relative to market cap and follows a pre‑arranged plan.

Market effects

Sector

None; insider sale does not affect the broader healthcare services sector.

Regional

None; limited to CRL shareholders.

Global

Low; isolated to a single micro‑cap insider transaction.

Counterpoint

What could challenge this read

The sale could be interpreted as a lack of confidence, but the 10b5‑1 plan suggests it is routine.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of laboratory services and products to the pharmaceutical and biotech industries.

  • Insider
    Shannon M. Parisotto

    Chief Executive Vice President, Discovery & Safety Assessment.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

OCT 21
$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

stockstotrade.com3 min
OCT 21
$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

timothysykes.com3 min
SEP 24
$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

investing.com2 min
SEP 17
$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min